- Home
- APWC vs KPTI Comparison
APWC vs KPTI Comparison
Compare APWC & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APWC
- KPTI
- Stock Information
- Founded
- APWC 1996
- KPTI 2008
- Country
- APWC Taiwan
- KPTI United States
- Employees
- APWC N/A
- KPTI N/A
- Industry
- APWC Telecommunications Equipment
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- APWC Industrials
- KPTI Health Care
- Exchange
- APWC Nasdaq
- KPTI Nasdaq
- Market Cap
- APWC 30.1M
- KPTI 29.8M
- IPO Year
- APWC 1997
- KPTI 2013
- Fundamental
- Price
- APWC $1.50
- KPTI $3.86
- Analyst Decision
- APWC
- KPTI Strong Buy
- Analyst Count
- APWC 0
- KPTI 5
- Target Price
- APWC N/A
- KPTI $61.00
- AVG Volume (30 Days)
- APWC 4.1K
- KPTI 147.0K
- Earning Date
- APWC 03-31-2025
- KPTI 05-07-2025
- Dividend Yield
- APWC N/A
- KPTI N/A
- EPS Growth
- APWC N/A
- KPTI N/A
- EPS
- APWC 0.17
- KPTI N/A
- Revenue
- APWC $472,672,000.00
- KPTI $145,237,000.00
- Revenue This Year
- APWC N/A
- KPTI $4.87
- Revenue Next Year
- APWC N/A
- KPTI $16.29
- P/E Ratio
- APWC $8.94
- KPTI N/A
- Revenue Growth
- APWC 11.02
- KPTI N/A
- 52 Week Low
- APWC $1.24
- KPTI $3.51
- 52 Week High
- APWC $2.02
- KPTI $21.60
- Technical
- Relative Strength Index (RSI)
- APWC 45.43
- KPTI 29.47
- Support Level
- APWC $1.46
- KPTI $3.51
- Resistance Level
- APWC $1.59
- KPTI $4.09
- Average True Range (ATR)
- APWC 0.04
- KPTI 0.61
- MACD
- APWC -0.00
- KPTI -0.13
- Stochastic Oscillator
- APWC 20.59
- KPTI 10.42
About APWC Asia Pacific Wire & Cable Corporation Ltd. (Bermuda)
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in owning operating companies engaged in the power cable, telecommunication cable, enameled wire, and electronic cable industry. It also provides project engineering services to customers. Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and Rest of the World.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.